GSK Investigational Site

Ede 6716 RP

0 studies enrolling now · 10 studies all time

What they study most

Atherosclerosis, Crohn's Disease, Neoplasms, Prostate, Pulmonary Disease, Chronic Obstructive, Sepsis

Studies at this site

• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease — Completed
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• ARI103094-Follow-Up Study for REDUCE Study Subjects — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• SB-480848 In Subjects With Coronary Heart Disease — Completed